Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Research And Development Expense of $142.02 million for the year ending 2025.
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -17.1% in Research And Development Expense from 2024 to 2025.
- This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), ROCKET PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 2,439.6%.
- Historical annual values: Fiscal year 2025: $142.02 million | Fiscal year 2024: $171.24 million | Fiscal year 2023: $186.34 million | Fiscal year 2022: $165.57 million | Fiscal year 2021: $125.48 million | Fiscal year 2020: $105.44 million | Fiscal year 2019: $57.91 million | Fiscal year 2018: $53.27 million | Fiscal year 2017: $14.92 million | Fiscal year 2016: $5.99 million | Fiscal year 2015: $12.55 million | Fiscal year 2014: $5.59 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: